← boardnext 2026-12next 2027-09
ZYME
Zymeworks BC Inc.distress 1/10 · well-funded / low risk$23.00-2%today-19% from 52w high
Oncology 1
Lead: HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma
Revenue
pre-revenue
Liquidity
$543M
Runway
7.2 yrs
Shares 1y
-3%
Price & events
-2.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
-4.9%
1W
-3.7%
1M
-16.2%
3M
-1.0%
6M
+61.0%
1Y
+121.6%
2Y
-35.1%
5Y
-53.0%
All
Overview
- Market Cap
- $1.68B
- Volume
- 34.11K
- 52 Week Range
- $12.02 – $28.56
- Total Shares
- 73.02M
- Float Shares
- 68.01M
- Short %
- 8.86%
- % Held by Insiders
- 1.30%
- % Held by Institutions
- 103.01%
- RVOL
- 0.06x
- Beta
- 1.13
Pipeline stages · 3 programs
ZW191
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ZW251
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ZW171
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | ZW191fast track | Advanced Solid Tumors | — | active not recruiting |
| 2027-09 Estimated 50% readout ~2027-10-01 | Phase 1 | ZW251 | Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor | — | recruiting |
| 2025-09-30 | Phase 1 | ZW171 | Mesothelin-expressing Advanced Cancers | 32 | terminated |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 20
- first half of 2027Guided 55%enrollment completesecondaryPhase 3zanidatamab · Enrollment completion expected in EmpowHER-303 trialSEC 8-K
- later in 2027 or early 2028Guided 70%readoutPhase 3zanidatamab · Top-line data readout from EmpowHER-303 trialSEC 8-K
- August 25, 2026Confirmed 100%PDUFAPDUFAzanidatamab · PDUFA target action date for zanidatamab sBLASEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 3zanidatamab · Second interim overall survival analysis for HERIZON-GEA-01 trialSEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)ZW209 · IND filing for ZW209 planned in first half of 2026SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)zanidatamab · Jazz to submit supplemental Biologics License ApplicationSEC 8-K
- 2026-06-28partnershipEntry into definitive merger agreement to acquire TheravanceSEC 8-K
- April 2026conferencedata presentationsecondaryPresentation of R&D portfolio at AACR Annual MeetingSEC 8-K
- first quarter of 2026conferencedata presentationsecondaryzanidatamab · Data presentation at major medical meetingSEC 8-K
- 1Q 2026regulatory submissionFiled (NDA/BLA)Ziihera (zanidatamab-hrii) · Supplemental BLA submission for first-line GEASEC 8-K
- 2026-03-02partnershipZiihera · Zymeworks sold 30% of future Ziihera royalties to a subsidiary and obtained a $250M loan from Royalty Pharma.SEC 8-K
- February 2026conferencedata presentationsecondarypasritamig · Clinical data presented at ASCO-GUSEC 8-K
- 2025trial initiationsecondaryPhase 1ZW251 · Initiation of Phase 1 study for ZW251 expected in 2025SEC 8-K
- 4Q-2025readoutPhase 3zanidatamab · topline PFS data expectedSEC 8-K
- 4Q-2025trial initiationsecondaryPhase 1ZW191 · Dose optimization at 6.4 mg/kg and 9.6 mg/kg expected to initiateSEC 8-K
- October 2025conferencedata presentationsecondaryPhase 1ZW191 · Phase 1 data presented at AACR-NCI-EORTC; ORR 53% overall, 64% gynecologicalSEC 8-K
- September 2025trial initiationsecondaryPhase 3pasritamig · J&J initiated Phase 3 trial; triggered $25M milestoneSEC 8-K
- 2025-09-02trial discontinuedZW171 · Voluntarily discontinue clinical development of ZW171 Phase 1 trial after dose escalation; benefit-risk profile unfavorableSEC 8-K
- 2025-09-01partnershippasritamig · Achieved $25.0M development milestone from J&J for pasritamig Phase 3 trial entrySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $39 (+71% upside) · 12 analysts
- 2026-07-07Truist SecuritiesBuy
- 2026-06-30Wells FargoOverweight
- 2026-06-03HC Wainwright & Co.Buy
- 2026-05-08Wells FargoOverweight
- 2026-03-09Evercore ISI GroupOutperform
- 2026-03-06HC Wainwright & Co.Buy
Competitors — HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma
- JAZZJazz Pharmaceuticals plc$15.7B · D0
Recent news
- 2026-07-22N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development - Business Wire
- 2026-07-21FairJourney Bio Announces Scientific Program and Leadership for The Antibody Series 2026 - Business Wire
- 2026-07-17Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm
- 2026-07-16Zymeworks to report Q2 2026 financial results on August 6 - scanx.trade
- 2026-07-16Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 - Quiver Quantitative
- 2026-07-16Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Toronto Star
- 2026-07-16Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - GlobeNewswire
- 2026-07-15Zymeworks (NASDAQ:ZYME) Is In A Strong Position To Grow Its Business - 富途牛牛
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.